Cowen & Co. Maintains a Hold Rating on Ionis Pharmaceuticals Inc (IONS)

By Jason Carr

Cowen & Co. analyst Ritu Baral maintained a Hold rating on Ionis Pharmaceuticals Inc (IONSResearch Report) today. The company’s shares closed last Monday at $61.46.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 18.4% and a 41.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.

Ionis Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $73.75, representing a 16.5% upside. In a report issued on October 11, Morgan Stanley also maintained a Hold rating on the stock with a $63.00 price target.

See today’s analyst top recommended stocks >>

Ionis Pharmaceuticals Inc’s market cap is currently $8.64B and has a P/E ratio of 22.07. The company has a Price to Book ratio of 6.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.